Overview
- Jaime Moreno, EsSalud's president, publicly rejected reports of oncology drug shortages and said managers at Almenara, Rebagliati and Sabogal certified stocked pharmacies.
- Moreno announced an enlarged review by EsSalud’s Órgano de Control Institucional that will examine a truncated emergency-decree procurement route now under scrutiny.
- The insurer has set aside S/196 million to buy 742 medicines for cancer and other serious conditions and has already used inter-hospital loans to keep treatments running.
- The Ministerio Público has opened an investigation into alleged irregularities in recent medicine purchases and that probe is continuing as EsSalud increases internal oversight.
- If audits or the prosecutor’s findings prompt changes, hospitals could face new procurement controls and patients may see more stable supply through the planned purchases and redistribution measures.